We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Should Invest in Arcturus Stock Now
Read MoreHide Full Article
Arcturus Therapeutics Holdings Inc. (ARCT - Free Report) is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies.
San Diego, CA-based Arcturus has developed the first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, Kostaive, in the world. The company has a collaboration agreement with renowned vaccine company CSL Seqirus for making innovative mRNA vaccines.
Last week, Arcturus and CSL announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) approved/authorized the updated formulation of the sa-mRNA COVID-19 vaccine, Kostaive, targeting the variant JN.1.
The regulatory body approved Kostaive targeting the variant JN.1 for active immunization to prevent COVID-19 in adults aged 18 years and above in Japan. In November 2023, Japan's MHLW approved Kostaive, the sa-mRNA COVID-19 vaccine, for initial vaccination and booster for adults aged 18 years and above.
Year to date, shares of Arcturus have plunged 34.2% against the industry’s growth of 0.5%.
Image Source: Zacks Investment Research
ARCT’s Other Pipeline Development Activities
Earlier this month, the FDA cleared the company’s investigational new drug (IND) application for its product candidate, ARCT-032, which is being developed for the treatment of cystic fibrosis (CF).
Following the FDA clearance of the IND, Arcturus will now begin a phase II multiple ascending dose study to evaluate the safety, tolerability and efficacy of ARCT-032 in people with CF.
ARCT-032 is developed using the company’s proprietary Lunar lipid-mediated aerosolized platform, which follows a novel mechanism of action of delivering the cystic fibrosis transmembrane conductance regulator messenger RNA to the lungs.
The FDA has previously granted an Orphan Drug designation and Rare Pediatric Disease designation to ARCT-032 for the treatment of CF.
The company is developing another pipeline candidate, ARCT-810, in a phase II study for the treatment of ornithine transcarbamylase deficiency.
Arcturus’ top line currently comprises collaboration revenues from partners and grant revenues. Successful development of these candidates should boost the company’s growth prospects.
ARCT’s Rank & Rising Estimates
Arcturus currently sports a Zacks Rank #1 (Strong Buy).
In the past 60 days, the Zacks Consensus Estimate for Arcturus’ 2024 loss per share has narrowed from $4.39 to $2.60. Also, the Zacks Consensus Estimate for 2025 has moved from a loss of 45 cents to earnings of 21 cents.
The company has a sound cash position, which it believes is sufficient to fund operations into the first quarter of fiscal 2027.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.43. Year to date, shares of ILMN have lost 7.2%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 62.5%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.33 to 32 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.22. Year to date, shares of FULC have plunged 52.9%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Here's Why Investors Should Invest in Arcturus Stock Now
Arcturus Therapeutics Holdings Inc. (ARCT - Free Report) is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies.
San Diego, CA-based Arcturus has developed the first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, Kostaive, in the world. The company has a collaboration agreement with renowned vaccine company CSL Seqirus for making innovative mRNA vaccines.
Last week, Arcturus and CSL announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) approved/authorized the updated formulation of the sa-mRNA COVID-19 vaccine, Kostaive, targeting the variant JN.1.
The regulatory body approved Kostaive targeting the variant JN.1 for active immunization to prevent COVID-19 in adults aged 18 years and above in Japan. In November 2023, Japan's MHLW approved Kostaive, the sa-mRNA COVID-19 vaccine, for initial vaccination and booster for adults aged 18 years and above.
Year to date, shares of Arcturus have plunged 34.2% against the industry’s growth of 0.5%.
Image Source: Zacks Investment Research
ARCT’s Other Pipeline Development Activities
Earlier this month, the FDA cleared the company’s investigational new drug (IND) application for its product candidate, ARCT-032, which is being developed for the treatment of cystic fibrosis (CF).
Following the FDA clearance of the IND, Arcturus will now begin a phase II multiple ascending dose study to evaluate the safety, tolerability and efficacy of ARCT-032 in people with CF.
ARCT-032 is developed using the company’s proprietary Lunar lipid-mediated aerosolized platform, which follows a novel mechanism of action of delivering the cystic fibrosis transmembrane conductance regulator messenger RNA to the lungs.
The FDA has previously granted an Orphan Drug designation and Rare Pediatric Disease designation to ARCT-032 for the treatment of CF.
The company is developing another pipeline candidate, ARCT-810, in a phase II study for the treatment of ornithine transcarbamylase deficiency.
Arcturus’ top line currently comprises collaboration revenues from partners and grant revenues. Successful development of these candidates should boost the company’s growth prospects.
ARCT’s Rank & Rising Estimates
Arcturus currently sports a Zacks Rank #1 (Strong Buy).
In the past 60 days, the Zacks Consensus Estimate for Arcturus’ 2024 loss per share has narrowed from $4.39 to $2.60. Also, the Zacks Consensus Estimate for 2025 has moved from a loss of 45 cents to earnings of 21 cents.
The company has a sound cash position, which it believes is sufficient to fund operations into the first quarter of fiscal 2027.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Illumina, Inc. (ILMN - Free Report) , Krystal Biotech, Inc. (KRYS - Free Report) and Fulcrum Therapeutics, Inc. (FULC - Free Report) , each sporting a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.43. Year to date, shares of ILMN have lost 7.2%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 62.5%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.33 to 32 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.22. Year to date, shares of FULC have plunged 52.9%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.